Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K is filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on June 7, 2020, with the report date reflecting the earliest event of June 7, 2020. The filing details a material definitive agreement involving a registered direct offering and a concurrent private placement of equity securities.

Key Financial Metrics and Transaction Details

  • Offering Structure: Registered direct offering of 1,747,704 shares of Common Stock at $4.5145 per share, plus a concurrent private placement of warrants.
  • Gross Proceeds: Approximately $7.89 million.
  • Net Proceeds: Approximately $7.07 million (after fees and expenses).
  • Investor Warrants: 873,852 warrants issued (50% of shares purchased), exercisable immediately at $5.18 per share, expiring in 5.5 years.
  • Placement Agent Compensation: 7.0% cash fee ($552,300), 1.0% management fee ($78,900), and warrants to purchase 122,339 shares (7.0% of shares sold) at $5.6431 per share.
  • Closing Date: June 10, 2020.

Material Changes and Unusual Items

The primary material change is the dilution of existing shareholders due to the issuance of new shares and warrants. A significant unusual item involves the adjustment of existing warrants:

  • Anti-Dilution Adjustment: Warrants issued in May 2019 (444,444 shares) had an exercise price of $5.70. Due to the current offering price of $4.5145, the exercise price of these May 2019 warrants will be reduced to the lower of the offering price or the lowest one-day volume-weighted average price during the five trading days starting June 8, 2020.
  • Lock-Up Provisions: The Company is prohibited from selling Common Stock or convertible securities for 45 days post-closing (with exceptions). For one year, the Company cannot issue securities with prices that vary based on the trading price of Common Stock or reset based on future events, except for an "at-the-market" facility after the 45-day period.

Guidance, Outlook, and Risks

The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operational performance. The primary risks and contingencies disclosed relate to the capital raise:

  • Registration Obligation: The Company must file a Form S-1 registration statement for the resale of shares underlying the warrants by July 7, 2020.
  • Unregistered Securities: The warrants and underlying shares are unregistered and cannot be sold in the U.S. without an effective registration statement or exemption.
  • Indemnification: The Company has agreed to indemnify the placement agent for certain liabilities arising from the offering.

Investor Verification Checklist

  • Verify the exact adjusted exercise price of the May 2019 warrants based on the five-day VWAP calculation starting June 8, 2020.
  • Confirm the total number of outstanding shares post-closing to assess immediate dilution impact.
  • Review the attached press releases (Exhibits 99.1 and 99.2) for any additional strategic use of proceeds not detailed in the 8-K text.
  • Monitor the filing of the Form S-1 registration statement for warrant shares by the July 7, 2020 deadline.
  • Check the Company's cash balance post-closing to confirm the net proceeds of $7.07 million were received.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.